Chuanmei Sanhuang Powder Veterinary Grade API is a standardized multi-herb powder supplied for downstream processing into tablets, injections, capsules, powders, granules, premix, and solutions. In manufacturer release documentation the product is identified by model code CSH-VG-25A; the designation is site-specific and is not a pharmacopoeial monograph. The material consists of selected fractions of Scutellaria baicalensis root, Coptis chinensis rhizome, and Rheum palmatum root processed to reduce coarse botanical debris, limit bioburden, and hold marker content within an assay window. The oral-grade powder and the finer solution-grade fraction are distinct release states. The powder itself is not administered parenterally; injectable solutions are prepared from a purified extract intermediate or from a low-endotoxin grade that is subsequently sterile-filtered.

The API is released against supplier certificate limits that reflect both pharmacopoeial test methodology and production-scale blending behaviour. Moisture is the first processing boundary. At residual moisture exceeding 6.5%, the dried herb matrix forms lumps larger than 2.0 mm during ribbon blending; therefore, the release limit is set at ≤ 5.0%. Particle size is controlled to D90 ≤ 150 µm for oral solid dosage forms, while the solution intermediate is sieved or milled to D90 ≤ 75 µm to reduce clarification burden. Bulk density ranges from 0.42 g/mL to 0.58 g/mL, and tapped density ranges from 0.55 g/mL to 0.75 g/mL, yielding a Hausner ratio of 1.25–1.35. That range is acceptable for capsule tamping and wet granulation but is marginal for direct compression without glidant.

What In-Process Limits Keep Blend Uniformity Within an Acceptable Variance on a Continuous Premix Line?

Blend uniformity in premix manufacture is governed by particle size, residual moisture, and the order of addition. The API is not added as the first component to a mineral carrier. A 1:10 pre-blend with dextrose or ground corn cob is prepared before introduction into a double-ribbon mixer filled to 70% of working volume. Dry mixing beyond 15 min can elevate electrostatic fines and double the relative standard deviation of marker recovery. Release specifications therefore include particle-size distribution, loss on drying, ash, heavy metals, and microbial limits. The following certificate-of-analysis profile represents the oral veterinary-grade release state; injectable intermediates require additional endotoxin and bioburden criteria.

When the API Is Processed into Injectable Solutions, Pyrogen Removal Becomes the Rate-Limiting Step

The raw powder is not suitable for parenteral compounding. Injectable solutions are prepared only from a highly purified aqueous extract or from a low-endotoxin grade whose bacterial endotoxin burden is verified by limulus amebocyte lysate method aligned with Ph. Eur. 2.6.14 / USP <85>. A release limit of 0.25 EU/mg is applied if the solution will be administered by the intravenous route; for intramuscular products, some regulatory submissions accept 0.5 EU/mg, but the lower limit reduces batch rejection risk when dilution volumes vary. Particulate contamination in the finished solution is monitored according to USP <788>. Prefiltration bioburden of the API extract should remain below 10 CFU/100 mL before a 0.22 µm sterilizing filter train. Insoluble botanical residues must be removed by centrifugation followed by plate filtration; if clarification is omitted, membrane capacity on a 0.45 µm polyethersulfone membrane can fall below 5 L/m². Published data for the specific endotoxin reduction factor of this product across ultrafiltration cassettes is limited; scale-up trials should verify log reduction values using a molecular weight cutoff not above 10 kDa when high-molecular-weight endotoxin aggregates are present.

Premix manufacture introduces a different failure mode: segregation. In a double-ribbon mixer, the powdered API can migrate upward during mixing because of its low particle density relative to mineral carriers such as limestone and dicalcium phosphate. Pre-blending at 1:10 dilution reduces this effect. The API is not added directly to trace mineral premix because moisture and metal-ion contact can accelerate marker degradation; the preferred sequence is to blend the API with a non-reactive carrier, then add vitamin and mineral fractions. If the premix is stored above 25 °C and 60% relative humidity, clumping and surface discoloration may appear within 30 days. Finished feed premix stability should be confirmed by HPLC assay at the final inclusion rate rather than inferred from API-stability data alone.

The Compression Route Fails When the Hausner Ratio Exceeds 1.45

During tablet manufacture, the API is added to a high-shear granulator after dry pre-blending with microcrystalline cellulose and crospovidone. Wet massing is conducted at impeller 250–350 rpm and chopper 1500 rpm for 3–6 min; the dried herbal matrix has high water uptake capacity, so binder solution must be added by metering pump rather than poured. End granule moisture is held at 2.5–4.0% before compression on a rotary tablet press. Compaction force is adjusted to produce tablet hardness 60–100 N; excessive force can induce capping because fibrous plant residues create weak fracture planes. Capsule filling is less sensitive: the powder may be filled after sieving through a 0.8 mm screen, provided the Hausner ratio remains below 1.35. Granules for direct administration are produced by wet granulation and dried in a fluid-bed dryer with inlet air 60–70 °C; outlet air temperature is held below 45 °C to protect thermolabile marker constituents. Direct compression formulations without wet massing require a glidant and a highly compressible filler because the API alone has poor compactability.

Solution dosage forms are not produced by simple reconstitution of the dry powder. The solution-grade fraction is extracted in purified water at 40–50 °C under high-shear stirring. Baicalin is weakly acidic and has low water solubility at neutral pH; a phosphate-citrate buffer at pH 6.8–7.2 or a permitted co-solvent is required to prevent visible precipitation within 12 h. After extraction, the liquid is centrifuged, clarified through plate filtration, and optionally passed through a 0.45 µm prefilter. Terminal sterilisation is acceptable only if thermal stability data support autoclaving; otherwise aseptic filtration is used. The final solution should be protected from light because marker compounds in Sanhuang preparations can undergo photodegradation when exposed to direct UV light for more than 8 h.

Marker Reproducibility and Supply-Grade Differences Across Crude Powders, Standardized Extracts, and This Veterinary Grade

Competing products are often sold as simple milled herb mixes without marker standardization. Under those conditions, berberine hydrochloride and baicalin content can vary between batches because seasonal raw material alkaloid fluctuation shifts the assay value. A fixed tablet compression formula then produces assay drift and potential label-claim failure. This veterinary-grade API is standardized to a predefined marker range reported as mg/g on the dried basis, not as a single-point value. The difference is not limited to marker content: crude botanical powders generally carry higher microbial burden, less controlled particle size, and no endotoxin specification. The table below summarises operational distinctions that directly affect formulation decisions.

The API therefore occupies an intermediate position between unprocessed botanical mass and single-marker isolates. It retains multiple constituents rather than isolating berberine hydrochloride or baicalin alone, which alters dissolution kinetics and finished-product assay strategy. Because the powder contains fibrous plant fragments, it is not a drop-in replacement for pure synthetic berberine or purified baicalin in pharmaceutical formulas. Published data for the exact dissolution profile of this multi-component API in feed matrices is limited; formulators should verify lot-specific swelling and gelling behaviour before committing to a continuous granulation run.